Citation, commencement, application and expiry

1. —(1) This Order may be cited as the Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (England, Wales and Scotland) Order 2024.

(2) This Order comes into force on 3rd June 2024.

(3) This Order does not apply to Northern Ireland.

(4) This Order ceases to have effect at the end of 2nd September 2024.

Interpretation

2. In this Order—

“ 2012 Regulations ” means the Human Medicines Regulations 2012( 2 );

“ approved UK prescriber ” means an authorised prescriber who is an appropriate practitioner in relation to any prescription only medicine by virtue of regulation 214(3)(a), (c), (d) or (e) of the 2012 Regulations( 3 ) (sale or supply of prescription only medicines);

“ authorised prescriber ” means any person who is an appropriate practitioner for the purposes of regulation 214 of the 2012 Regulations (subject to any limits on their prescribing rights included in that regulation);

“ current national identity document ” means a document that is a current national identity document for the purposes of the rules under section 3(2) of the Immigration Act 1971( 4 ) (general provisions for regulation and control);

“gonadotrophin-releasing hormone (“GnRH”) analogue” means a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin;

“ NHS prescription ” means an order for a medicinal product which is in the form of a prescription or direction and which is issued by an authorised prescriber as part of arrangements for the provision of services as part of—

“ private prescription ” means an order for a medicinal product which is in the form of a prescription or direction which is not a NHS prescription (whether or not it would otherwise be considered a private prescription);

“ sale ” means sale by retail (and “selling” has a corresponding meaning);

“ specified document ” has the meaning given in rule 35(1H) of the election rules in Schedule 1 to the Representation of the People Act 1983( 9 ) (Parliamentary election rules – questions to be put to voters);

“ supply ” means supply in circumstances corresponding to retail sale (which includes supply by way of administration but does not include supply for the purposes of a clinical trial that has been authorised by the licensing authority);

“ UK birth certificate ” means a certified copy of a United Kingdom birth register entry or a valid certificate of birth compiled from such an entry.

Prohibition on the sale or supply of medicinal products consisting of or containing gonadotrophin-releasing hormone analogues

3. Subject to articles 4 to 6, the sale or supply of a GnRH analogue is prohibited.

Exception for NHS prescriptions

4. Article 3 does not apply to a sale or supply in pursuance of a NHS prescription.

Exception for private prescriptions: patients aged 18 or over

5. —(1) Article 3 does not apply to a sale or supply in pursuance of a private prescription, if—

(a) Condition A is met; and

(b) if the private prescription is a prescription, rather than a direction, which is or purports to be in accordance with the requirements of regulation 217, 218, 219 or 219A of the 2012 Regulations( 10 ) (which relate to requirements for paper and electronic prescriptions), either Condition B or Condition C is met.

(2) Condition A is that on the day the private prescription was issued, the patient in respect of whom it was issued was aged 18 or over.

(3) Condition B, which applies if the prescription was issued by an approved UK prescriber, is that—

(a) the prescription has included within it the patient’s age and is annotated by the prescriber with “SLS”; or

(b) the person to whom the GnRH analogue is to be sold or supplied produces to the person selling or supplying the GnRH analogue a specified document, a UK birth certificate or a current national identity document that verifies, to the reasonable satisfaction of the person selling or supplying the GnRH analogue, the age and identity of the person to or for whom the GnRH analogue is to be sold or supplied.

(4) Condition C, which applies if the prescription was issued by an authorised prescriber who is not an approved UK prescriber, is that the person to whom the GnRH analogue is to be sold or supplied produces to the person selling or supplying the GnRH analogue a specified document, a UK birth certificate or current national identity document that verifies, to the reasonable satisfaction of the person selling or supplying the GnRH analogue, the age and identity of the person to or for whom the GnRH analogue is to be sold or supplied.

Exception for private prescriptions: patients aged under 18

6. —(1) Article 3 does not apply to a sale or supply in pursuance of a private prescription, if—

(a) Condition A is met;

(b) if the private prescription is a prescription, rather than a direction, which is or purports to be in accordance with the requirements of regulation 217, 218, 219 or 219A of the 2012 Regulations( 11 ) (which relate to requirements for paper and electronic prescriptions), Condition B is met;

(c) if the private prescription was issued on or after 3rd June 2024, Condition C is met; and

(d) unless the sale or supply is to or for a person who, on any occasion, started a course of treatment with a GnRH analogue before 3rd June 2024, Condition D is met.

(2) Condition A is that on the day the private prescription was issued, the patient in respect of whom it was issued was aged under 18.

(3) Condition B is that—

(a) the prescription has included within it the patient’s age and is annotated by the prescriber with “SLS”; or

(b) if the prescription was issued before 3rd June 2024, the person to whom the GnRH analogue is to be sold or supplied produces to the person selling or supplying the GnRH analogue a specified document, a UK birth certificate or a current national identity document that verifies, to the reasonable satisfaction of the person selling or supplying the GnRH analogue, the age and identity of the person to or for whom the GnRH analogue is to be sold or supplied.

(4) Condition C is that the private prescription was issued by an approved UK prescriber.

(5) Condition D is that the purpose for which the private prescription was issued is a purpose other than treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both.

(6) For the purposes of paragraph (1)(d), a person is treated as having started a course of treatment with a GnRH analogue if, in the six month period before 3rd June 2024, that person was issued with a NHS or private prescription for a GnRH analogue, whether or not the prescription has been dispensed or the prescribed GnRH analogue has been taken by that person before 3rd June 2024.

(7) For the purposes of paragraph (5), treatment is treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination or both if it is, viewed objectively, treatment for that purpose, as gender dysphoria and gender incongruence are ordinarily understood as part of medical practice in Great Britain.